grant
Intratumor Heterogeneity as a Correlate of Clinical Outcome in Patients Avoiding Radical Cystectomy
Organization RESEARCH INST OF FOX CHASE CAN CTRLocation PHILADELPHIA, UNITED STATESPosted 1 Apr 2026Deadline 31 Mar 2031
NIHUS FederalResearch GrantFY2026AddressAdjuvant ChemotherapyAdjuvant Drug TherapyAfter CareAfter-TreatmentAftercareAnimal ModelAnimal Models and Related StudiesAppearanceBiological MarkersBiologyBladderBladder CancerBladder Urinary SystemBladder removalBody TissuesCDDPCancer PatientCancerousCancersCell BodyCellsChemoresistanceCis-diammine-dichloroplatinumCis-diamminedichloridoplatinumCis-diamminedichloro Platinum (II)Cis-dichloroammine Platinum (II)Cis-platinous Diamine DichlorideCis-platinum IICis-platinum II Diamine DichlorideCisplatinCisplatinaCisplatinumClinicalClinical TrialsClinical assessmentsClonalityCollectionCysplatynaCystectomyDNADNA AlterationDNA DamageDNA InjuryDNA Sequence AlterationDNA mutationDataDeoxyribonucleic AcidDetectable Residual DiseaseDichlorodiammineplatinumDistantEnrollmentEventFutureGeneticGenetic AlterationGenetic ChangeGenetic HeterogeneityGenetic RiskGenetic defectGenetic mutationGenetics-MutagenesisGoalsGuidelinesHeterogeneityHistologicHistologicallyHouse miceHumanImmunityIn complete remissionInduction TherapyInterceptIntratumoral heterogeneityKnowledgeLesionLifeMalignantMalignant - descriptorMalignant Bladder NeoplasmMalignant NeoplasmsMalignant TumorMalignant Tumor of the BladderMalignant neoplasm of urinary bladderMeasuresMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMethodologyMethodsMinimal Residual DiseaseModern ManMolecular FingerprintingMolecular ProfilingMonitorMonitoring for RecurrenceMus musculusMutagenesisMutagenesis Molecular BiologyMutagenic ProcessMutationMutation DetectionNEOADJNatural HistoryNeoadjuvantNeoadjuvant TherapyNeoadjuvant TreatmentNeoplasm MetastasisNormal TissueNormal tissue morphologyOperative ProceduresOperative Surgical ProceduresOutcomePathologicPathologic MutagenesisPathologic Mutagenic ProcessPatient SelectionPatientsPedigreePeyrone's ChloridePeyrone's SaltPhysiciansPlatinum DiamminodichloridePositionPositioning AttributePrimary NeoplasmPrimary TumorProcessProteinsRadical CystectomyRecurrenceRecurrentRecurrent NeoplasmRecurrent tumorResidualResidual NeoplasmResidual TumorsResidual stateRiskSafetySamplingSecondary NeoplasmSecondary TumorSequence AlterationShapesSurgicalSurgical InterventionsSurgical ProcedureTestingTimeTissuesTranslatingTumor TissueUrinary Bladder CancerUrinary Bladder Malignant TumorUrineUrotheliumWorkactive methodactive techniqueactive treatmentanalyzing longitudinalbio-markersbiologic markerbiomarkercancer cell genomecancer genomecancer metastasischemoresistantchemotherapychemotherapy resistancechemotherapy resistantcis dichlorodiammineplatinumcis platinum compoundcis-Diaminedichloroplatinumcis-Diamminedichloroplatinumcis-Diamminedichloroplatinum(II)cis-Dichlorodiammineplatinum(II)cis-Platinumclinical significanceclinically significantcomplete responsedriver lesiondriver mutationenrollentire genomeexperienceexperimentexperimental researchexperimental studyexperimentsfull genomegenetic evolutiongenetic pedigreegenome mutationgenome sequencinggenomic alterationheterogeneity in tumorsimprovedindexinginduction therapiesintra-tumoral heterogeneityintratumor heterogeneityintravesicalliquid biopsylongitudinal analysismalignancymodel of animalmolecular profilemolecular signaturemouse modelmurine modelmuscle invasive bladder cancerneoplasm recurrenceneoplasm/cancernovelpatient profilepedigree structurepost treatmentprecancerprecancerouspremalignantprofiles in patientsprospectiveremote locationreproductive organresidual diseaseresponsestandard of caresub-clonal heterogeneitysubclonal heterogeneitysurgerysurveillance strategytooltumortumor cell metastasistumor genometumor heterogeneityurinaryurinary bladdervariant detectionwhole genome
Description preview
PROJECT SUMMARY/ABSTRACT
In 2025, patients and physicians are seeking to avoid radical cystectomy - a life altering, complicated, and
expensive surgery that is often employed in the effort to cure bladder cancer - in situations where complete
response to neoadjuvant therapy has been achieved. To address this desire, two clinical trials testing…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click